New blood tests that look at different forms of PSA and other proteins are better than the old PSA test at finding dangerous prostate cancers and avoiding false alarms.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether PHI and 4Kscore consistently outperform PSA in identifying aggressive prostate cancer across diverse populations and settings.
A systematic review and meta-analysis of all prospective studies comparing PHI, 4Kscore, and PSA in men with PSA 4–10 ng/mL, using biopsy-confirmed high-grade cancer (Gleason ≥7) as the endpoint.
Whether men with elevated PHI or 4Kscore are more likely to be diagnosed with aggressive prostate cancer over time.
A prospective cohort of 10,000 men aged 50–70 with PSA 4–10 ng/mL, measured for PHI and 4Kscore, followed for 5 years with biopsy and cancer grading to assess predictive accuracy for high-grade disease.
Whether men with aggressive prostate cancer had significantly higher PHI or 4Kscore values than men with indolent cancer or no cancer.
A case-control study of 1,000 men with Gleason ≥7 prostate cancer vs. 1,000 with Gleason ≤6 or no cancer, with archived serum samples analyzed for PHI and 4Kscore.
Whether using 4Kscore or PHI instead of PSA reduces unnecessary biopsies without missing aggressive cancers.
A multicenter RCT of 8,000 men with PSA 4–10 ng/mL randomized to biopsy based on PSA alone vs. PSA + 4Kscore, with primary outcome: reduction in unnecessary biopsies and detection rate of Gleason ≥7 cancer.
Expert consensus on whether PHI and 4Kscore should be integrated into screening guidelines.
A consensus panel of 20 urologists and pathologists evaluating evidence for PHI/4Kscore adoption using standardized criteria.